Major bleeding risk higher for dabigatran than for warfarin, study suggests

JANNA LAWRENCE

首页> 外文期刊>The pharmaceutical journal >Major bleeding risk higher for dabigatran than for warfarin, study suggests

【24h】

Major bleeding risk higher for dabigatran than for warfarin, study suggests

机译：研究表明达比加群的主要出血风险高于华法林

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The oral anticoagulant dabigatran is associated with a higher incidence of major bleeding compared with warfarin, especially for black patients and those with chronic kidney disease, according to the authors of a new study published in JAMA Internal Medicine. For clinicians managing patients at risk of blood clots, the newer oral anticoagulants were a welcome addition to available treatment options because they do not require the intense monitoring needed for warfarin therapy. However, studies examining the risk of bleeding associated with these newer agents are inconclusive.

机译：据JAMA Internal Medicine发表的一项新研究的作者说，与华法林相比，口服抗凝剂达比加群与严重出血的发生率更高，特别是对于黑人患者和患有慢性肾脏疾病的患者。对于管理有血栓风险的患者的临床医生而言，较新的口服抗凝剂是现有治疗方案的可喜补充，因为它们不需要华法林治疗所需的严格监控。但是，研究与这些新型药物相关的出血风险的研究尚无定论。

著录项

来源
《The pharmaceutical journal》 |2014年第7838期|共1页
作者
JANNA LAWRENCE;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Major bleeding risk higher for dabigatran than for warfarin, study suggests [J] . JANNA LAWRENCE The pharmaceutical journal . 2014,第7837a7838期

机译：研究表明达比加群的主要出血风险高于华法林
2. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population [J] . Amin Alpesh, Keshishian Allison, Trocio Jeffrey, Current medical research and opinion . 2017,第9期

机译：与美国医疗保险人口的华法林相比，中风/全身栓塞患者的中风/全身栓塞患者的严重出血和相关成本
3. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin A propensity score matched analysis [J] . Lip Gregory Y. H., Keshishian Allison, Kamble Shital, Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis . 2016,第5期

机译：在阿哌沙班，达比加群，利伐沙班或华法林引发的非瓣膜性房颤患者中主要出血风险的真实世界比较A倾向评分匹配分析
4. Study Suggests Breast Density Alone Not a Risk Factor for Cancer [C] . Linda Brooks, Maureen Morley Scientific Assembly and Annual Meeting of the Radiological Society of North America . 2015

机译：研究表明，单独的乳房密度不是癌症的危险因素
5. Precision Medicine in Atrial Fibrillation: A Risk Model for Management with Dabigatran v. Warfarin [D] . Ader, Jeremy. 2018

机译：心房颤动的精密药：Dabigatran v管理的风险模型。华法林
6. Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban dabigatran rivaroxaban or warfarin: a real‐world observational study in the United States [O] . Gregory Y. H. Lip, Xianying Pan, Shital Kamble, -1

机译：由阿哌沙班达比加群利伐沙班或华法林引发的非瓣膜性房颤患者的主要出血风险：一项在美国的真实世界观察性研究
7. EFFECT OF AGE AND RENAL FUNCTION ON THE RISKS OF STROKE AND MAJOR BLEEDING WITH DABIGATRAN COMPARED TO WARFARIN: AN ANALYSIS FROM THE RE-LY STUDY [O] . Healey Jeff S., Eikelboom John, Wallentin Lars, 2010

机译：年龄和肾功能对达比加群与华法林的卒中和大出血风险的影响：一项真实研究的分析

Major bleeding risk higher for dabigatran than for warfarin, study suggests

摘要

著录项

相似文献

相关主题

期刊订阅